Zydus Lifesciences Q4 Revenue Rises 18% YoY to ₹6,528 Crore

22 May 2025 , 12:16 PM

Zydus Lifesciences Ltd has reported upbeat results for the quarter ended March 31, 2025 driven by strong growth in its US formulations business. The US formulations business recorded a strong 24% YoY growth and 30% sequential rise, resulting in revenue of ₹3,130.7 crore, led by volume increase and new product introductions.

In constant currency, the US unit turned in $363 million of revenue, versus $285 million in Q3 FY25, and $304 million in Q4 FY24. The US market now forms nearly 50% of the company’s total topline and is a significant growth driver for Zydus Lifesciences.

Profitability and Margins:

The company’s net profit fell 1% YoY to ₹1,171 crore. The fall in profit was mainly on account of a one-time loss of ₹220 crore it suffered during the quarter. Consolidated revenue for the March quarter rose 18% YoY to ₹6,528 crore. This compares with ₹5,533.8 crore in the same quarter last year.

EBITDA grew 30% YoY to ₹2,126 crore. By contrast, the company’s EBITDA was ₹1,630.5 crore in the same quarter last year. EBITDA margin increased by 310 bps to 32.6% in Q4 FY25 from 29.5% in Q4 FY24. This is a testament to strong operating leverage and a favorable product mix.

Dividend Announcement:

For FY25, the Board of Directors had proposed a final dividend of ₹11 per equity share (1100% on the face value of ₹1). The dividend is payable pending shareholder approval at the August 12, 2025 Annual General Meeting (AGM). There is currently no record date for the dividend.